TIPAL: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole, a randomised placebo-controlled multi-centre clinical trial The TIPAL research study is focusing on treating idiopathic pulmonary fibrosis (IPF) with the addition of lansoprazole. Lansoprazole reduces the amount of acid your stomach makes. It’s used for indigestion, heartburn, acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is […]
Category: RCT
Recent Posts
- This PF Awareness Month, Action for Pulmonary Fibrosis is asking everyone to Take Action for PF.
- Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis
- Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction
- September is Pulmonary Fibrosis Awareness Month
- The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis
- Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
- September is Pulmonary Fibrosis (PF) Awareness Month
- Exercise training in idiopathic pulmonary fibrosis: is it of benefit?
- Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosisand type 2 diabetes mellitus: a national claims‑based cohort analysis
- Plasticity towards Rigidity: A Macrophage Conundrum in
Pulmonary Fibrosis - TIPAL
- Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
- Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
- Mitochondrial Quality Control in COPD and IPF
- Idiopathic Pulmonary Fibrosis (IPF): An Overview
- UK Petition, March 2023
- Pulmonary Fibrosis Research and Education Hub
- Hello world!
Recent Comments
No comments to show.
